Medtronic Plc MDT

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

Medtronic (NYSE:MDT) received FDA 510(k) clearance for its LigaSure RAS Maryland jaw device for the Hugo robotic-assisted surgery system in the U.S. The LigaSure RAS Maryland jaw brings Medtronic's established vessel sealing technology into Hugo procedures for general, gynecologic and urologic surgery settings. This authorization broadens the portfolio of energy instruments available on Hugo, giving hospitals another option as they evaluate robotic surgery platforms. The LigaSure RAS...

Intellectual Property Owners Education Foundation (IPOEF) announced that William J. Peine, Ph.D., Vice President of Research and Technology with the Surgical business of Medtronic, a global leader in healthcare technology, has been selected as the recipient of the 2026 Inventor of the Year Award for his contributions to patented innovations supporting the company's Hugo™ robotic-assisted surgery (RAS) system.

Company recognized for improving healthcare outcomes through technologyNORTHAMPTON, MA / ACCESS Newswire / September 30, 2026 / today announced it has been named to the prestigious FORTUNE 2026 ‘Change the World' list for its Touch Surgery™ ecosystem and Healthy Neighbor program through LABS. The annual list showcases companies working to combat global issues and drive positive social or environmental change.

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced regulatory milestones for software used with two cardiac ablation platforms. This includes U.S. Food and Drug Administration (FDA) clearance and CE Mark for the latest Affera™ Prism-2 Mapping Software. The company also obtained CE Mark for the PulseSelect ProxBox™ Adapter with Proximity Indicator software. These milestones expand integrated mapping and tissue-proximity capabilities across the Medtronic cardiac ablat

Rodolphe Katra has joined from Medtronic to lead GE HealthCare’s efforts to connect devices, software and data.

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.

Cyted Health, a leading gastrointestinal molecular diagnostics company, today announced the appointment of Thomas West as Chair of its Board of Directors and Non-Executive Director, and the appointment of Robert Epstein as a Non-Executive Director, to support the company's continued commercial growth across the US and UK.

A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T